Purchase Of Shares In Teva Pharmaceutical Industries Limited (TEVA) By Dethlefs Sven

At the last check on Friday, Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) stock was up $0.19, moving up 2.60 percent to $7.70. The average number of shares traded per day over the past five days has been 9,947,347 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.17 fall in that time frame. In the last twenty days, the average volume was 8,759,981, while in the previous 50 days, it was 8,774,543.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Since last month, TEVA stock retreated -26.01%. Shares of the company fell to $7.23 on 05/12/22, the lowest level in the past month. A 52-week high of $11.55 was reached on 04/08/22 after having rallying from a 52-week low of $7.23. Since the beginning of this year, TEVA’s stock price has dropped by -6.24% or -$0.34, and marked a new high 14 times. However, the stock has declined by -33.26% since its 52-week high.

Teva Pharmaceutical Industries Limited (TEVA) last reported insider trading activity 67 days ago on Mar 07. Dethlefs Sven, the EVP, North America Commercial of the company, disposed of 6,993 shares for $7.37 on Mar 07. It resulted in a $51,515 divestment by the insider. Daniell Richard sold 22,576 shares at an average price of $7.37 on Mar 07. The insider now owns 43,182 shares following the transaction. On Mar 07, Executive VP Global Operations Drape Eric sold 11,334 shares at $7.37 apiece. The transaction was valued at $83,494.

Valuation Metrics

The stock’s beta is 1.19. Besides these, the trailing price-to-sales (P/S) ratio of 0.60, the price-to-book (PB) ratio of 0.89, and the price-to-cash flow ratio of 15.96 may also be considered.

The latest dividend of $0.0850 per share was paid out, remained unchanged from last year’s $0.0850.

Financial Health

In the three months ended December 30, Teva Pharmaceutical Industries Limited’s quick ratio stood at 0.70, while its current ratio was 1.10, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending December 30 was 2.23, and the total debt-to-equity ratio was 2.45. On the profitability front, the trailing twelve-month gross margin is 49.80% percent. In the year ended December 30, EBITDA margin amounted to 27.75%, whereas operating margins totaled 3.70%. Based on annual data, TEVA earned $7.59 billion in gross profit and brought in $15.88 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 4.50%. Return on equity (ROE) for the past 12 months was -6.10%.

In Teva Pharmaceutical Industries Limited’s quarter-end financial report for December 30, it reported total debt of $20.84 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. TEVA’s revenue fell -8.77% to $4.1 billion during the quarter, while net income inched up to $3.66 billion. While analysts expected Teva Pharmaceutical Industries Limited to report $0.73 quarterly earnings, the actual figure was $0.77 per share, beating the consensus estimate by 5.50%. During the quarter, the company generated -$391.0 million in EBITDA. The liabilities of Teva Pharmaceutical Industries Limited were 36.8 billion at the end of its most recent quarter ended December 30, and its total debt was $23.59 billion. The value of shareholders’ equity is $1.11 billion.

Technical Picture

This quick technical analysis looks at Teva Pharmaceutical Industries Limited’s (TEVA) price momentum. With a historical volatility rate of 41.30%, the RSI 9-day stood at 30.77% on 12 May.

With respect to its five-day moving average, the current Teva Pharmaceutical Industries Limited price is down by -2.17% percent or -$0.17. At present, TEVA shares trade -24.73% below its 20-day simple moving average and -4.48% percent below its 100-day simple moving average. However, the stock is currently trading approximately -1.54% below its SMA50 and -20.85% below its SMA200.

Stochastic coefficient K was 14.36% and Stochastic coefficient D was 9.89%, while ATR was 0.39. Given the Stochastic reading of 23.04% for the 14-day period, the RSI (14) reading has been calculated as 32.97%. As of today, the MACD Oscillator reading stands at -0.27, while the 14-day reading stands at -0.63.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles